Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Inclusion Criteria: 1. Provides written informed consent before any assessment is performed 2. Is male or female aged ≥18 3. Has previously completed a Novartis-sponsored hepatitis C study and received alisporivir 4. Has achieved SVR24 5. Is able to comply with the visit schedule Exclusion Criteria: 1. Use of any investigational drugs within 5 half-lives of enrollment, or within 30 days of that medication, whichever is longer. 2. Use or planned use to start a new course of hepatitis C therapy. 3. No additional exclusions are to be applied by the Investigator, in order to ensure that the study population is representative of all eligible patients.